Back to top
more

Cardiovascular Systems, Inc. (CSII)

(Delayed Data from NSDQ)

$39.49 USD

39.49
435,746

+1.98 (5.28%)

Updated May 3, 2019 04:00 PM ET

After-Market: $39.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain DaVita (DVA) in Your Portfolio

by Zacks Equity Research

DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from its core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

Cardiovascular Systems (CSII) Q3 Earnings Top, View Tapered

by Zacks Equity Research

Cardiovascular Systems (CSII) rides high on a year-over-year rise in both Coronary and peripheral device revenues.

Cardiovascular Systems (CSII) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 150.00% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Cardiovascular Systems (CSII) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiovascular Systems Gains on Global Growth & Innovation

by Zacks Equity Research

Cardiovascular Systems (CSII) hopes that new product menu will deliver minimum 10% growth in its core business during the second half of fiscal 2019.

Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Merit Medical (MMSI) registers solid expansion in adjusted gross margins in fourth-quarter 2018.

Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues

by Zacks Equity Research

Veeva Systems (VEEV) continues benefiting from its flagship Vault platform in fourth-quarter fiscal 2019.

Wright Medical (WMGI) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Wright Medical's (WMGI) top-line growth in fourth-quarter 2018 can be attributed to solid performance by the Upper and the Lower Extremities segments.

Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts

by Zacks Equity Research

Bruker's (BRKR) CALID and NANO groups hold promise.

Here's Why Investors Should Buy DexCom (DXCM) Stock Now

by Zacks Equity Research

Solid growth at the Sensor, Transmitter and Receiver segments provide DexCom (DXCM) a competitive edge in the MedTech space.

CVS Health Rides on Aetna Synergy, PBM Selling Season Modest

by Zacks Equity Research

With regard to its 2019 PBM selling season, CVS Health (CVS) notes that the net benefits from this selling season are expected to be modest on Anthem-related headwinds.

Here's Why Investors Should Hold DaVita (DVA) Stock Now

by Zacks Equity Research

DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.

Medidata's (MDSO) Margins Under Pressure, Competition Rife

by Zacks Equity Research

Medidata (MDSO) suffers from cutthroat competition in the clinical trial solutions market at the moment.

Here's Why Investors Should Buy Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.

Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock

by Zacks Equity Research

Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.

Baxter's Acute Therapies Profile Strong, Competition Rife

by Zacks Equity Research

Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.

Here's Why Investors Should Retain AmerisourceBergen Stock

by Zacks Equity Research

AmerisourceBergen (ABC) expects to witness solid growth at the Pharmaceutical Distribution segment in the long term.

Here's Why Investors Should Retain Accuray (ARAY) Stock Now

by Zacks Equity Research

A series of software upgrades is likely to provide Accuray (ARAY) a competitive edge in the radiation-oncology space.

Here's Why You Should Buy Wright Medical (WMGI) Stock Now

by Zacks Equity Research

A growing orthopedic market and strong international expansion make Wright Medical (WMGI) a promising investment pick at the moment.

Here's Why You Should Invest in McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson's (MCK) solid prospects in the pharmaceutical and medical supplies distribution market look promising.

Here's Why You Should Hold Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical's (ISRG) solid exposure to robotics & medical mechatronics is commendable. Its robot-based da Vinci Surgical System for minimally-invasive surgery is an added positive.

Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Meet

by Zacks Equity Research

Cardiovascular Systems (CSII) benefits from year-over-year growth in both Coronary and peripheral device segments.

Company News For Jan 31, 2019

by Zacks Equity Research

Companies In The News Are: CSII,T,HES,ADP

Cardiovascular Systems (CSII) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 125.00% and 0.92%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?